Integra Therapeutics announces new pre-clinical data at 28th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) [Video]

BARCELONA, Spain, May 13, 2025 /PRNewswire/ — Integra Therapeutics, a global leader in creating cutting-edge gene-writing tools to improve the efficacy, precision and safety of advanced therapies, today announced it will be presenting new pre-clinical data at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from May 13 to 17 in New Orleans.

“The presentation at ASGCT marks an important milestone in our work to develop safer and more capable cell engineering with our gene-writing platform with double digit editing efficiencies and multi gene integration for the next generation of cell therapies for oncological and autoimmune diseases” explains Dr Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics.

For the first time, the Integra Therapeutics’ technology has been used to created CAR-T cells, demonstrating the expression of more complex CARs (bispecific and with a kill switch) in a single DNA donor and simplifying the production …